Monitoring of minimal residual disease (MRD) after allogeneic (allo)-SCT for myelofibrosis (MF) allows recognizing the depth of remission and thus guides application of appropriate therapeutic interventions. MPL W515L/K mutations, which are detected in 5-10% of JAK2V617F-negative patients, may be useful for this purpose. Using a highly sensitive quantitative PCR method, we tested 90 patients with MF who underwent allo-SCT for the presence of MPL W515L/K mutations. Two patients with primary MF were found to harbor MPLW515L while no patient was positive for MPLW515K mutation. Both patients were JAK2V617F negative and cleared the mutation rapidly after allo-SCT and remained negative for a median follow-up of 19 months. The results of molecular monitoring correlated well with other remission parameters such as normalization of peripheral blood counts and morphology and complete donor chimerism. We conclude that MPLW515L can be cleared after allo-SCT and hence may be used as an MRD marker in a proportion of JAK2V617F-negative MF patients.
Introduction
Myelofibrosis (MF) is one of several myeloproliferative disorders and is associated with a poor prognosis in a significant number of affected patients.
1 Allogeneic (allo)-SCT is the only known curative treatment, which is able to reverse the fibrosis in bone marrow and restore normal hematopoiesis. 2 With the advent of reducedintensity conditioning, allo-SCT became a feasible curative treatment option also for elderly patient because of the low associated treatment-related toxicity; however, relapse remains a major problem. 3 Monitoring of remission after allo-SCT for MF depending only on the criteria established by the International Working Group for Myelofibrosis Research and Treatment is often misleading. A complete remission according to those criteria warrants the resolution of the disease-related clinical signs and symptoms as well as cytopenias. Persistence of such signs after allo-SCT may be caused by several coexisting treatment-related conditions such as GVHD, graft dysfunction or toxic medications. Using specific molecular markers of malignant cells such as the JAK2V617F detected in 450% of MF patients, close monitoring of the molecular remission state has become possible. Donor lymphocyte infusions can be successfully used in treating relapse after allo-SCT but are probably associated with increased morbidity because of triggering of GVHD. 4 Using a pre-emptive strategy depending on a highly sensitive Taqman PCR specific for JAK2V617F, molecular relapse or minimal residual disease (MRD) after allo-SCT can be early detected. Applying donor lymphocyte infusions at the stage of molecular relapse is more likely to be effective and less toxic than in the case of full-blown clinical relapse. 5 However, early interventions are only applicable in the presence of a reliable disease-specific molecular marker and a sensitive and feasible monitoring method. Mainly in the patients with primary MF (PMF) and essential thrombocythemia (ET) who lack JAK2 V617F, other mutations such as MPL W515L/K were detected in B5% of cases. 6 These mutations might be promising candidates for MRD measurement in the post transplant period. Several quantitative PCR assays have been developed to detect these mutations with varying sensitivities. 7, 8 We report here on the use of a sensitive real-time PCR assay to follow MPLW515L/K post transplant in two patients with PMF who were identified to carry the mutation.
Design and methods

Patients
Q-PCR for MPL W515L/K was retrospectively performed on peripheral blood samples preceding allo-SCT from 90 patients with histologically proven PMF (n ¼ 65), post-polycythemia vera MF (post-ET MF, n ¼ 15) or post-essential thrombocythemia MF (post-ET MF, n ¼ 10). All patients had given written informed consent in accordance to the declaration of Helsinki. Allo-SCT was performed according to the local protocol described earlier. 9 Methods DNA samples. Stored DNA samples from patients with MF were used in this retrospective study. DNA was isolated from 200 ml whole blood using QIAamp columns (Qiagen, Hilden, Germany). The procedure regularly results in 4-12 mg DNA in a final volume of 200 ml. In each PCR reaction, 10 ml DNA (200-600 ng) were used. For patients found to be positive for one of the two mutations, all available DNA samples representing different time points after allo-SCT were submitted to PCR analysis.
Real-time TaqMan PCR. Real-time quantitative PCR was performed on a Chromo 4 thermocycler (Biorad, Munich, Germany). Primer and probe sequences were identical to those used earlier by Chaligne et al. 10 in their semiquantitative genotyping approach. Primers were from Eurofins MWG Operon (Ebersberg, Germany), FAM-and VIC-labeled MGB-probes from Applied Biosystems (Darmstadt, Germany). Duplex PCR was performed for the mutated (using the FAM probe) and the wild-type (using the VIC probe) allele in the same reaction tube. To do so, primer concentrations were optimized for highly sensitive duplex reactions based on primer matrices. Plasmids for MPL wild type, W515L, and W515K kindly provided by Alessandro M Vannucchi 8 were used as templates during optimization. Integrity of wildtype and mutated alleles were confirmed using DNA sequencing.
Q-PCR was performed in 25 ml reaction mixes containing 10 ml template DNA, 200 nM Taqman probe, 150 nM of each primer and 12.5 ml from ready-to-use TaqMan Genotyping Master Mix from Applied Biosystems. After initial denaturation for 3 min, PCR was carried out for 45 cycles at standard conditions (94 1C: 15 s, 60 1C: 60 s). Control wells without template DNA were included in each assay. Q-PCR results were analyzed using Opticon Monitor Software 3.1.32.
Initial screening of DNA samples was always carried out in duplicates, for both the W515L and W515K mutations. For absolute quantification, two independent serial dilutions of the plasmids containing W515L and W515K mutations, respectively, into genomic DNA from healthy individuals were generated. Based thereon, standard curves could be obtained for either mutation using the abovedescribed duplex PCR and the DDct method as described earlier. 11 The amount of mutated and wild-type allele in every unknown sample thus might be determined by plotting the corresponding mean Dct value against the standard curve.
Results
Validation of MPLW515L/K PCR assay
In an initial step, serial dilutions of MPLW515K/L plasmids in water were tested to establish absolute sensitivity of the optimized Q-PCR method. For both mutated alleles, as few as 10 copies were readily detected by the Q-PCR approach used here.
To determine the sensitivity of both PCR reactions in a more realistic setting, MPLW515K/L plasmid DNA was mixed into genomic DNA from healthy donors at defined copy numbers. Both mutations were detectable at concentrations as low as 100 copies in 2.5 Â 10 5 genome equivalents corresponding to a sensitivity of 4 Â 10 -4 (0.04%).
To assess the specificity of the optimized Q-PCR technique used here, DNA samples from 46 healthy individuals were tested, and no sample was found to be positive for either MPL mutation. Non-template controls were always negative.
Next, we used our method to test 16 positive DNA samples with predetermined MPLW515L allele burden using pyrosequencing (from the Institute of Pathology, Hannover Medical School). We found a good correlation between the two methods ( Figure 1) .
Screening of the patients for MPLW515L/K mutations
Seventy-six patients of the whole group (67/90; 74%) had previously been proven positive for the JAK2V617F mutation as assessed with a Q-PCR method described elsewhere.
9 MPLW515L was identified in two of the 90 patients (2.2%), whereas none was positive for the MPLW515K. Both patients had no evidence of the JAK2V617F mutation.
Follow-up of the MPLW515L positive patients
In both patients with idiopathic MF, the MPLW515L mutation was cleared within the first 6 weeks after allo- 
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SCT. The first patient, a female of 67 years at the time of allo-SCT, had no significant short-term complications. She underwent prolonged immunosuppressive therapy because of extensive chronic GVHD. In our retrospective analysis, MPLW515L Q-PCR was negative in all serial blood samples obtained from the patient after allo-SCT between 21 and 882 days post transplant. At the time of this report-and 2.5 years from allo-SCT-she was doing well with full-donor chimerism and complete hematological remission.
Patient 2 was a 66-year-old female who suffered from a poor graft function 100 days after allo-SCT. She received a CD34 þ stem cell boost and recovered gradually thereafter. After a follow-up of 1.5 years from allo-SCT, she was doing well and still under mild immunosuppression because of residual chronic hepatic GVHD. She showed a full-donor chimerism and was in stable complete hematological and molecular remission as RQ-PCR was negative for the MPLW515L at all available follow-up samples after allo-SCT (days þ 41 to þ 528 post transplant).
Discussion
About 50% of patients with MF harbor the JAK2V617F mutation, which can therefore be used as an MRD marker post transplant. 12 In the remaining patients, estimation of persisting residual disease depends largely on chimerism measurement. However, establishment of sensitive, ideally quantitative PCR assays for less frequent cytogenetic abnormalities associated with MF could offer additional, usually even more sensitive means to assess the molecular remission state. This might be of particular importance when other remission criteria become equivocal. MPL mutations were recently described as novel genetic abnormalities affecting the gene encoding the thrombopoietin receptor and confer cytokine-independent cell growth through constitutive activation of the JAK/STAT pathway. 6 Out of several so far identified recurrent MPL mutations, only the W515L and W515K are pathogenetically relevant and able to promote spontaneous phosphorylation of downstream pathways. Moreover, cell lines transduced with MPLW515L and W515K are able to induce clinical disease when injected in mice. 10 Those mutations are reported in B10% of MF and 4% of ET patients, most being negative for the JAK2V617F. 6, [13] [14] [15] [16] However, coexistence of the two mutations is possible as cases of monoclonal or biclonal expression of both of them have been already published. 17, 18 To detect MPLW515L/K mutations, genotyping techniques using allele-specific PCR were first used with qualitative or semiquantitative results and a 3-5% sensitivity level. 6, 19 Pyrosequencing is a quantitative technique resulting in a sensitivity of only 5%. 20, 21 Melting curve analysis using LightCycler assay was also reported to be sensitive for mutant allele burden of at least 5%. 16 Several Taqman PCR techniques were recently reported and confer maximally 0.1% sensitivity; some of them use DNA from granulocytes rather than whole peripheral blood. 7, 8 In our study, we optimized previously reported Q-PCR assays to be used for MRD assessment after allo-SCT. As we have shown for both MPL W515L/K mutations, the sensitivity of the used real-time PCR technique reached about one mutated allele per 2500 genome equivalents (4 Â 10 -4 or 0.04%). Also, negative PCR results obtained for 46 samples from healthy blood donors underline the high specificity of the PCR techniques used here. Based thereon, we were able to perform a rapid and convenient retrospective and screening for both MPLW515L/K mutations. Whole blood samples were sufficient to produce a good sensitivity allowing the detection of minimal mutational burden. This omits the necessity to select granulocytes before mutation analysis as carried out in earlier studies. 8 Overall, the incidence of MPLW515L mutation in our MF cohort was compatible with the previously known incidence rates. 6 Both MPLW515L-positive patients were JAK2V617F negative consistent with earlier findings. 15, 16 Importantly, despite the relevant mutant allele burden in both patients before allo-SCT, MPLW515L positive cells were not detectable very early after allo-SCT. In both patients, the mutation remained undetectable during the whole follow-up in well agreement with the absence of clinical or molecular relapse.
Chaligne et al. 19 have shown that MPLW515K mutations are already present in early hematopoietic stem and progenitor cells, including SCID-repopulating cells. For this reason and based on the experience with the JAK2V617F, it might well be expected that MPLW515L would become positive in the case of malignant relapse. Accordingly, we propose that MPLW515L and possibly MPLW515K mutations can be used as a minimal molecular disease marker in MF patients who otherwise lack other more obvious specific disease markers. Indeed, the results from this study support this assumption. Because of the rarity of these mutations, accumulating evidence from multiple centers is needed to reliably confirm these results.
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